Background: Considering the effectiveness of nebulized furosemide in asthma crisis that were non-responsive to the inhalational β-agonists , this study aimed to examine the effect of concomitant administration of furosemide (10 mg) and nebulized salbutamol (2.5 mg) on spirometry parameters in persistent asthma.

Materials and Methods: In this clinical trial, 53 patients (age, 18-75 years) with a 6-months history of persistent asthma were randomly allocated to two groups, the salbutamol (n=27) and salbutamol + furosemide (n=26) groups. Participants in each group were classified into the mild, moderate and severe persistent asthma on the basis of FEV1 . Participants were administered salbutamol or salbutamol + furosemide, and then the spirometry parameters were recorded 15 minutes after the completion of nebulization treatment . Before and after the treatment, mean and standard deviation of the spirometry parameters and their changes were calculated .

Results: Results showed no significant difference regarding the mean percentage change for FEV1 in the salbutamol (27.5%) and salbutamol + furosemide groups (25.83%) after the treatment (P=0.72). Moreover, no significant difference was seen between the two groups regarding the mean percentage changes in other parameters after the treatment (FVC, FEV1, PEF, MMEF, FEV1/FVC, P>0.25).

Conclusion: Concomitant administration of furosemide and salbutamol has no advantage over salbutamol in normalizing the spirometry parameters of persistent asthma.